- Home
- DXC vs HCM Comparison
DXC vs HCM Comparison
Compare DXC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | HCM |
|---|---|---|
| Founded | 1959 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DXC | HCM |
|---|---|---|
| Price | $15.12 | $13.54 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $15.33 | $13.75 |
| AVG Volume (30 Days) | ★ 2.2M | 25.4K |
| Earning Date | 10-30-2025 | 08-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1492.90 | N/A |
| EPS | ★ 2.03 | 0.53 |
| Revenue | ★ $12,714,000,000.00 | $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.54 |
| P/E Ratio | $7.46 | ★ $4.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.82 | $11.51 |
| 52 Week High | $23.75 | $19.50 |
Technical Indicators
Market Signals| Indicator | DXC | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 70.67 | 27.75 |
| Support Level | $11.82 | $14.11 |
| Resistance Level | $15.20 | $14.27 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | 0.24 | -0.05 |
| Stochastic Oscillator | 92.48 | 6.78 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.